PR Newswire·Nov 9, 2026, 9:15 AM ET

Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology

Illumina launches an early access program for an ultrasensitive molecular residual disease (MRD) research workflow utilizing duplex sequencing chemistry.
The workflow detects circulating tumor DNA (ctDNA) at 2.5 parts per million levels with high accuracy using low sample inputs of 5-10 nanograms.
Duplex sequencing analyzes both DNA strands to increase confidence in detection by distinguishing biological signals from sequencing errors.
The solution combines the NovaSeq X sequencing platform with DRAGEN bioinformatics software to support longitudinal whole-genome studies.
Representative studies demonstrated reproducible detection with quality scores exceeding Q65.
NYU Langone Health is an early access user applying the technology to in-house MRD research for disease recurrence analysis.
Kits for the early access program are scheduled to ship in the first quarter of 2027.
The standardized whole-genome workflow simplifies laboratory operations with a turnaround time of less than five days.
Forward-looking statements in the release note risks regarding shipment timing, manufacturing robustness, & product adoption.